• diffusion weighted imaging;
  • dynamic contrast enhanced magnetic resonance imaging;
  • magnetic resonance imaging;
  • magnetic resonance spectroscopic imaging;
  • prebiopsy;
  • prostate cancer


  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References

Introduction:  Existing screening investigations for the diagnosis of early prostate cancer lack specificity, resulting in a high negative biopsy rate. There is increasing interest in the use of various magnetic resonance methods for improving the yield of transrectal ultrasound-guided biopsies of the prostate in men suspected to have prostate cancer. We review the existing status of such investigations.

Methods:  A literature search was carried out using the Pubmed database to identify articles related to magnetic resonance methods for diagnosing prostate cancer. References from these articles were also extracted and reviewed.

Results:  Recent studies have focused on prebiopsy magnetic resonance investigations using conventional magnetic resonance imaging, dynamic contrast enhanced magnetic resonance imaging, diffusion weighted magnetic resonance imaging, magnetization transfer imaging and magnetic resonance spectroscopy of the prostate. This marks a shift from the earlier strategy of carrying out postbiopsy magnetic resonance investigations. Prebiopsy magnetic resonance investigations has been useful in identifying patients who are more likely to have a biopsy positive for malignancy.

Conclusions:  Prebiopsy magnetic resonance investigations has a potential role in increasing specificity of screening for early prostate cancer. It has a role in the targeting of biopsy sites, avoiding unnecessary biopsies and predicting the outcome of biopsies.

Abbreviations & Acronyms

apparent diffusion coefficient


American Urological Association


benign prostatic hyperplasia

CG =

central gland

Cho =


Cit =


Cr =



dynamic contrast enhanced magnetic resonance imaging


digital rectal examination


diffusion weighted imaging

1H MRS =

proton magnetic resonance spectroscopy


magnetic resonance imaging


magnetic resonance spectroscopic imaging


magnetization transfer imaging


magnetization transfer ratio


negative predictive value


positive predictive value


prostate-specific antigen

PZ =

peripheral zone

T1WI =

T1-weighted image

T2WI =

T2-weighted image


transrectal ultrasound

TZ =

transition zone


  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References

Despite its limitations, serum PSA is widely used for screening, early detection, staging and follow up of prostate cancer. The diagnosis of prostate cancer is based on systematic TRUS-guided 6–18 core needle biopsies. In current clinical practice, ultrasound-guided prostate biopsy is recommended for men who have abnormal DRE (regardless of PSA level) and/or elevated PSA level. A PSA level of less than 4 ng/mL is generally accepted in normal limits; however, cancer might be detected in as many as 15% of men with a PSA level less than 4 ng/mL.1 Recent AUA guidelines recommend obtaining baseline PSA for men aged 40 years and older with a minimum 10-year life expectancy, and do not recommend the use of a single threshold value of PSA to prompt a biopsy of the prostate.2,3

PSA is not specific to prostate cancer, and might be elevated due to other conditions resulting in unnecessary biopsies, especially in patients having PSA 4–10 ng/mL. The biopsy procedure is invasive and might suffer from sampling errors. Therefore, there is a need for a non-invasive diagnostic method with high sensitivity and specificity.

Imaging methods might have the potential to address some of these problems in prostate cancer assessment and management. MRI is at the forefront of the imaging modalities available and has shown potential in prostate cancer imaging. This is a result of the extraordinary capability of MRI to provide anatomical, metabolic and physiological information non-invasively in vivo. Various MR methods are used for obtaining anatomical and functional information. Anatomical/structural information is obtained with the use of T2WI, whereas the metabolic and functional state is obtained using 1H MRS, DWI and DCE-MRI. Recently, MTI has also been explored in prostate cancer. These MR methods, alone or in combination, have been shown to have a potential role in prostate cancer evaluation; for example, detection of prostate cancer, localization, tumor volume, staging, guiding targeted biopsy, tumor aggressiveness and radiation or focal therapy planning.

In the present review, we describe the potential role of prebiopsy MR investigations of the prostate. First, a brief description of various MR methods used for prostate cancer evaluation is provided, followed by discussion of clinical applications of prebiopsy MR investigations.

Role of magnetic resonance methods in prostate imaging

  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References


High-resolution T2WI using an endorectal coil provide an excellent depiction of prostatic zonal anatomy with the PZ showing higher signal intensity than the CG. Cancers located in the PZ of the prostate are usually seen as a low signal intensity lesion in a hyperintense PZ on a T2-weighted image (see Fig. 1).4 T2WI has limitations in detecting cancer in CG, because cancer and normal tissues both have low signal intensity in this region. A large variation in sensitivity (22–85%) and specificity (50–99%) of T2WI for prostate cancer detection has been reported.5 The sensitivity and specificity reported for local staging with MRI are in the range of 14.4–100% and 67–100%, respectively.5


Figure 1. T2-weighted axial MR images of (a) prostate of a volunteer, and (b) of a patient showing the tumor (arrows).

Download figure to PowerPoint


DCE-MRI technique makes use of an external contrast agent, such as gadolinium-diethylenetriamine pentaacetic acid, for improvement in contrast in the images and to assess vascular properties. Diffusion of contrast agent after injection is followed by rapid acquisition of images. Improvement in detection and characterization of prostate cancer has been reported by carrying out DCE-MRI at 1.5T and at 3T.6 The sensitivity and specificity for detection of prostate cancer achieved by using DCE-MRI alone has been reported to be in the range of 52–96% and 65–95%, respectively.5 DCE-MRI showed higher reader accuracy compared with T2WI in tumor localization at 3T.7 The potential of DCE-MRI in prostate imaging including detection, localization, staging and monitoring treatment has recently been reviewed.8


Diffusion weighted imaging generates contrast in images, which is sensitive to differences in the diffusion of water in tissues. This difference in diffusion properties among tissues might be quantified by ADC, obtained by acquiring DWI at multiple b-values. In general, malignant tissues tend to have more restricted diffusion than do normal tissues because of the high cell densities and abundance of intra- and intercellular membranes.9–13 Therefore, cancerous regions appear hyperintense on DWI and hypointense on an ADC map compared with normal regions. Figure 2 shows a DWI and ADC map obtained from a patient with prostate cancer. Lower ADC values in cancer compared with normal prostate tissue have been shown to have clinical utility in prostate cancer detection.14,15 In addition to differences in ADC value, mean FA values obtained using diffusion tensor imaging has been shown to distinguish cancerous and non-cancerous tissues.16,17


Figure 2. Representative example transverse images of prostate acquired from a patient diagnosed with prostate cancer on TRUS-guided biopsy (a) T2-weighted image, (b) diffusion weighted image at b = 1000 s/mm2 and (c) ADC map.

Download figure to PowerPoint

It has been shown that DWI in addition to T2WI significantly improved the accuracy of tumor detection beyond that achieved with T2WI alone.18 Despite significant differences in the mean ADC between malignant and normal tissues, individual variability might lower the diagnostic accuracy of ADC for prostate cancer detection and localization.14,15,18–20


MT utilizes the interaction of water protons with macromolecular protons to generate contrast among different tissues in image. A decrease in signal intensity attained by the MT effect is quantified by the MTR. Application of MTI has been shown to have potential in improving image contrast and tissue characterization, especially in brain imaging and MR angiography.21

There is sparse literature on the use of MTI in prostate cancer imaging. The first report on the application of MTI in prostate cancer appeared in 1999 in Japanese.22 Recently, we reported a detailed MTI in patients before biopsy and normal volunteers.23


Biochemical basis of 1H MRS of the prostate

Normal prostate and BPH tissues contain higher levels of Cit and Zn compared to all other tissues of the body.24 Extraordinarily high levels of Cit in the prostate are because of the limited activity of the enzyme, m-aconitase, responsible for converting Cit to isocitrate in Kreb's cycle.25 However, in prostate cancer tissue, Cit levels are decreased to less than 1000 nmol/g (from 8000 to 15 000 nmol/g).24,26–28

1H MRS of the prostate

Cit, Cho and Cr are the most common metabolites detected by MRS of the prostate in vivo. The resonance of methylene protons of Cit show a distinctive peak at approximately 2.6 ppm in the 1H MR spectrum, whereas the methyl protons of Cho and Cr appear at 3.2 and 3.0 ppm, respectively (see Fig. 3). MR spectrum acquired from the cancerous region shows decreased Cit and increased Cho, compared with the normal region of the prostate. The Cit and Cho levels observed by MRS are usually expressed by using ratios of the integral of the resonance peak of metabolites; for example, Cit/Cho, (Cit/[Cho + Cr]) or ([Cho + Cr]/Cit).29,30


Figure 3. Representative MRSI spectrum obtained and corresponding histopathology image showing (a,b) normal PZ, (c,d) BPH and (e,f) cancer tissue. Please note the large reduction of Cit and increase in Cho in prostate cancer compared with normal and BPH tissue.

Download figure to PowerPoint

MRSI, an advanced variation of MRS, has made it possible to acquire high-resolution proton spectra from the entire prostate in a clinically reasonable amount of time.31 Using 3D-MRSI, the (Cho + Cr)/Cit ratio was found to be a specific marker for prostate cancer, with 98% of the cancer ratios falling above three standard deviations of the mean healthy PZ value.31,32 High specificity of 3D-MRSI to identify cancer can be used to improve the ability of MRI to detect cancer within the prostate. MRSI of the prostate have high reproducibility to use this technique as a reliable tool in assessing tumor probability in the prostate.33 Scheidler et al. obtained 91% specificity with the use of combined MRI/3D-MRSI for detection of cancer, whereas high sensitivity (95%) was obtained when either test provided a positive result.34 The accuracy of MRI and MRSI for detection of prostate cancer is similar to that of a sextant biopsy, except in the prostate apex.35

Clinical applications of MR studies before biopsy

  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References

The focus of the majority of studies on MR in prostate cancer has been on staging the disease after cancer has been diagnosed on a prostate biopsy. Another important clinical question is selecting patients for biopsy from among those suspected to have cancer. Standard guidelines recommended biopsies for elevated PSA (4–10 ng/mL) or abnormal DRE are positive in less than 25% of the cases.36,37 Furthermore, prostate biopsies are associated with anxiety and morbidity, and increasing the number of cores increases the yield, but with associated complications. There is thus a clinical need for improving the selection of patients for a biopsy. Few recent reports addressed the potential of MR examination in improving selection of cases for biopsy and the yield of biopsies.38–42 The strategy of carrying out MR before biopsy might increase its clinical value and help circumvent some of the limitations. It might help in detection, targeting biopsies and predicting the presence or absence of cancer, resulting in a reduction in the number of biopsies carried out. In addition, carrying out a prebiopsy MRI also circumvents the problem of postbiopsy hemorrhage artifacts seen on MR images and hence, avoids the need to wait for 2–3 months for MR imaging after biopsy. Recently, it has been reported that the addition of prebiopsy MRSI and DWI to conventional prostate MR imaging have shown promising results in prostate imaging, with a significant increase of sensitivity and specificity of cancer detection.43

Diagnosis and characterization

The main focus of many prebiopsy MRI and MRSI studies has been to localize suspicious areas of malignancy in patients with elevated levels of PSA or abnormal findings on DRE, suggestive of prostate cancer. A recent study evaluated the potential role of prebiopsy MRI at 1.5T in 185 patients with a PSA level of 4.0–10.0 ng/mL.44 The study showed that combining MRI findings with PSA density provides high sensitivity and improves the specificity for the early detection of prostate cancer.44 The sensitivity, PPV and location match percentage of MRI before prostate biopsy in cancer detection have been reported as 84.8%, 75.7% and 89.3%, compared with after biopsy, 92.4%, 92.4% and 94.1%, respectively.45 The improved sensitivity of cancer detection by MRI has also been reported.45 Squillaci et al. studied 65 men with high levels of PSA, and suspicious areas at the TRUS using MR imaging and spectroscopy.46 The study reported sensitivity, specificity (PPV), NPV and accuracy for detection of prostate cancer as 89%, 77%, 78%, 69% and 83%, respectively for MRSI, whereas these values were 71%, 90%, 89%, 74% and 80%, respectively for combined MRI and MRSI.46Table 1 shows the summary of the sensitivity, specificity, PPV and NPV reported in the literature.

Table 1.  Summary of the sensitivity, specificity, PPV, NPV and accuracy of prebiopsy MR methods reported in the literature
MR methodStudySensitivitySpecificityPPVNPVAccuracy
MRIChoi et al.4584.8% 75.7%  
MRSISquillaci et al.4689%77%78%69%83%
Manenti et al.4775%89%88%74%87%
Villers et al.4877%91%86%85% 
MRI + MRSISquillaci et al.4671%90%89%74%80%
DWI + MRSIKumar et al.49100%33%64%  
DCE + MRSIPerdona et al.5071%48%19%91%85%
DWI + T2WI + DCETanimoto et al.5195%74%  86%
Kitajima et al.5281%96%  92%
DWI + DCEKozlowski et al.5387%74%   
MR targeted BiopsyHaffner et al.5495%100%  98%

The addition of MRS to MR imaging provides a higher specificity in tumor detection, and can be recommended as a problem-solving modality for patients with elevated PSA levels before biopsy.46 Manenti et al. reported MRI and MRSI on 39 patients with lesions suspicious of cancer on TRUS.47 The PSA level was greater than 4 ng/mL for all of the patients, and they carried out 10 core biopsy within 30 days after the MR investigation. Out of 17 patients showing voxels suspicious of malignancy, histology confirmed cancer in 15 patients. Their study reported sensitivity, specificity, PPV, NPV and accuracy as 75%, 89%, 88%, 74% and 87%, respectively for MRSI. These studies show the potential role and recommend prebiopsy use of MRS and MRI investigation in patients with high PSA levels and suspicious TRUS findings.46,47 However, Costouros et al. in a study of 40 patients using MRI and MRSI before biopsy reported significant improvement in the diagnostic accuracy by adding MRSI to MRI in patients with negative finding on prior biopsy or no prior biopsy.55 In their study, biopsy showed no cancer in 24, bilateral cancer in 11 and unilateral in five patients. Nonetheless, the authors indicated that when carried out before biopsy, MRSI and MRI might be considered as a secondary screening technique.

In men with high clinical suspicion for prostate cancer before biopsy, both EPI and FSI sequences show differences in ADC between normal PZ, central gland and cancer.56 Significantly lower mean ADC value of tumors compared with the mean value obtained for the normal PZ has been reported in a study of volunteers and patients with prostate lesions diagnosed by TRUS.57 The study showed the potential of DWI for characterizing tissues of the different regions of the prostate gland, and in distinguishing normal from cancerous tissues in a prebiopsy population.

Shimizu et al. evaluated the detection of prostate cancer by carrying out T2WI and DWI (and an ADC map) before biopsy in 122 patients.58 The sensitivity of T2WI, DWI and an ADC map was 41.2%, 56.7%, and 57.7%, respectively, and the PPV was 83.0%, 86.4% and 87.2%, respectively. Their study showed that MRI before a biopsy has a high detection rate for prostate cancer, particularly with the tumor size of more than 5 mm in short-axis diameter or 10 mm in long-axis diameter. We have previously reported DWI before biopsy, and determined a cut-off value of ADC (1.17 × 10−3 mm2/s) to predict malignancy in the PZ of the prostate.59 The diagnostic value of MRI and DWI before biopsy for the detection of prostate cancer has been evaluated at 3.0T. An accuracy between 71.4% to 100% has been achieved by combining MRI and DWI.60 Multimodal examination comprising T2WI, DCE-MRI and DWI is recommended for the diagnosis of prostate cancer at 3.0T.60 The diagnostic utility of DTI in prostate cancer has also been evaluated in men with suspicion of prostate cancer before biopsy. The mean fractional anisotropy, determined by carrying out DTI in men before prostate biopsy, has been reported to be significantly different for cancerous foci (0.30 ± 0.08) compared with the normal appearing gland (0.14 ± 0.04).17

Hara et al. carried out DCE-MRI in patients with elevated PSA followed by 14 core TRUS biopsy.61 DCE-MRI revealed 92.9% of the cancers with a specificity of 96.2%. The study showed that DCE-MRI can identify cancer in the prostate and might be useful to predict the histological grade. Villers et al. reported DCE-MRI in 92 men before biopsy and compared the data with the whole mount histology rather than with the TRUS biopsy data.48 The sensitivity, specificity, PPV and NPV were 77%, 91%, 86% and 85%, respectively, for foci greater than 0.2 cm3, and 90%, 88%, 77% and 95% for foci greater than 0.5 cm3.

Recently, we reported the use of MTI in prostate cancer.23 We found significantly higher mean MTR value for the PZ of patients who were positive for malignancy (8.29 ± 3.49) compared with patients who were negative for malignancy (6.18 ± 3.15) on TRUS-guided biopsy. The mean MTR for the PZ of controls (6.18 ± 1.63) was similar to that of patients who were negative for malignancy. More studies are required to explore further the role and the potential of MTI in prostate cancer.

There have been attempts to combine information from various MR methods to improve the accuracy of prostate cancer detection. MRSI, DCE-MRI and DWI provide information on metabolic activity, vascular properties and tissue changes, such as cellularity. Therefore, information obtained from combining these methods is expected to provide better results. We combined MRSI and DWI data, and found that regions of the PZ that were suspicious of cancer on MRSI using the metabolite ratio showed lower ADC values indicating suspicion for cancer.49 We also noted a positive correlation between metabolite ratio and ADC. The combined use of metabolite ratio and ADC values resulted in 100% sensitivity and NPV with a specificity of 33% and 64% PPV in predicting the presence of cancer when compared with the results of the TRUS-guided biopsy. The potential of DWI in combination with DCE-MRI has also been evaluated for achieving higher diagnostic sensitivity for prostate cancer. Kozlowski et al. observed significant differences in the MRI parameters obtained from tumor and normal prostate.53 Using DWI-derived parameters, the sensitivity and specificity values were 54% and 100%, respectively, and for DCE-MRI-derived parameters the sensitivity was 59% with 74% specificity. The combined use of parameters obtained from DWI and DCE-MRI resulted in increased sensitivity (87%) with 74% specificity.

Tanimoto et al. evaluated the potential of combining T2WI with DWI and DCE-MRI as screening methods for prostate cancer in 83 patients with elevated serum PSA.51 A sensitivity of 95% with 74% specificity and 86% accuracy for the detection of prostate cancer was obtained by combining T2WI, DWI and DCE-MRI. This was significantly different compared with T2WI alone or T2WI combined with DWI, and biopsy was used as the standard of reference. Kitajima et al. evaluated the potential of T2WI, DWI and DCE-MRI at 3T.52 When all the three methods were combined, the detection of cancer showed the sensitivity, specificity and accuracy as 81%, 96% and 92%, respectively. The authors suggested that the combination of these three methods might be a reasonable approach for the detection of prostate cancer.

A recent study evaluated the prebiopsy use of combined MRSI and DCE-MRI in prostate cancer diagnosis in men with PSA levels below 10 ng/mL.50 Using combined MRSI and DCE-MRI, and considering patients as single measurements, diagnostic accuracy, sensitivity, specificity, NPV and PPV of 85%, 71%, 48%, 91%, 19%, respectively, were obtained.50 Although the PPV was very low, the high NPV might serve to avoid unnecessary biopsies.50 The potential of the combined use of DTI and DCE-MRI for achieving higher diagnostic accuracy has also been reported.62 The combination of DTI and DCE-MRI gave significantly better accuracy in prostate cancer diagnosis than either technique alone.

Targeting biopsy

Targeted biopsies might improve the diagnostic yield even more than increasing the number of biopsies.63 MR examination carried out before biopsy might help to determine the position of suspicious areas of malignancy, allowing more accurate biopsy of the prostate by targeting the needle on such areas. Hence, accurate targeted biopsy might limit the need for multiple repeat biopsies. We reported MRSI examination in 83 men with abnormal DRE or elevated PSA before biopsy.39 MRSI-derived coordinates were used to target TRUS-guided biopsy needle on suspicious areas for malignancy on MRSI (see Fig. 4). Out of 44 patients having voxels suspicious of malignancy on MRSI, just 11 were found to have malignancy on biopsy. We found a detection rate of 25% with MRSI-directed TRUS-guided biopsy, whereas the detection rate was 9% in another group of 120 patients without MRSI guidance. Another interesting observation was 100% NPV achieved in this study. Haffner et al. compared MRI-targeted biopsies with extended systematic biopsies in 555 patients.54 For significant prostate cancer detection, sensitivity, specificity and accuracy for targeted biopsies were 0.95, 1.0 and 0.98, respectively. The values for extended systematic biopsies were 0.95, 0.83 and 0.88, respectively. The detection accuracy of significant prostate cancer by targeted biopsies was significantly higher compared with extended biopsies.54 Targeted biopsies detected 16% more grade 4 and 5 cases than extended systematic biopsies.54 MRI targeted biopsies based on prebiopsy MRI-detected lesions have been reported to result in increased detection rate, volume and grade of anterior prostate cancer compared with 12 cores systematic biopsy.64


Figure 4. (a) Sagittal section of T2-weighted image of prostate showing determination of the distance from the base of the prostate of the transverse section containing the suspicious voxel. (b) Voxel grid overlaid over T2-weighted transverse image of the corresponding section showing the distance of the suspicious voxel from midline of the prostate (c) MR spectrum obtained from the voxel showing increased Cho and decreased Cit. (d) TRUS image of MRSI-directed TRUS-guided biopsy of the prostate. The needle mark on the TRUS image shows the site of biopsy (reprinted from Kumar et al.39 with permission from John Wiley & Sons Limited).

Download figure to PowerPoint

The findings of MR investigations before biopsy of prostate might also prove to be important in patients with raised PSA and previous negative biopsy results. The circumstances for these patients are comparable to patients suspicious of prostate cancer in respect that they can benefit by MR investigations for improved detection or targeted biopsies, which might avoid the need for multiple biopsies. In these cases, the results of MR investigation might also indicate that the reason for elevated PSA levels might be other than cancer. Recently, many researchers have reported the use of MRSI to target needle biopsies under TRUS guidance for the detection of prostate malignancy in patients with previous negative TRUS biopsies.65–71 The application of MRI and MRS to target biopsies in patients with previous negative prostate biopsies and persistently elevated PSA levels appears to be significant.72

Yuen et al. showed that MRSI has the potential to direct biopsy in these patients with 100% sensitivity, 58% specificity, 100% PPV and 79% accuracy for detecting prostate cancer.65 Schmuecking et al. used pre-interventional, fused, high-resolution T2WI with parametrically analyzed DCE-MRI and proton MRS for a precise biopsy for the detection of prostate cancer, and for the delineation of intraprostatic subvolumes for intensity modulated radiation therapy in patients with elevated PSA and/or a previously negative biopsy.73 Sciarra et al. reported a prospective randomized study analyzing the role of MRSI and DCE-MRI in the detection of prostate tumor foci in patients with persistently elevated PSA and prior negative biopsy.74 A total of 180 eligible cases were randomized into two groups; group I of 90 patients who had a second random prostate biopsy, whereas group II (n = 90) underwent an MR investigation and targeted biopsy of suspicious areas. In group I, cancer was detected in 22 of 90 cases (24.4%), whereas 41 of 90 cases (45.5%) were positive for cancer in group II. Their study concluded that the combination of MRSI and DCE-MRI showed the potential to guide biopsy to cancer foci in patients with a previously negative TRUS biopsy.74

MRI data itself has been shown to have the potential to guide prostate biopsies without TRUS.75–78 Special biopsy systems developed for such purpose require additional technical design considerations, such as MR compatibility, precision, size and safety.78,79 These biopsy systems work under either manual or robotic control.78,80,81

Predicting malignancy on prostate biopsy

Gleason grades are based on the appearance of the prostatic glandular architecture under low-power magnification. The greater the deviation from normal glandular architecture, the higher the Gleason grade. A Gleason grade of 1 represents the acini that look like normal prostate acini, and a grade of 5 represents highly abnormal and undifferentiated acini. The Gleason score is obtained by adding the most common Gleason grade and the next most common Gleason grade present in a sample. Higher Gleason grade and Gleason score represents more aggressive cancer and worse prognosis. Generally, the TRUS biopsy technique underestimates the Gleason grade of the cancer compared with the radical prostatectomy specimen because of the inherent sampling error.82 This has the potential to alter treatment strategies, as treatment decisions are often based on the Gleason score on the biopsy. Prebiopsy MRI has the potential to localize and direct the TRUS-biopsy for more accurate biopsy. The addition of MRSI to T2WI improves the information about Gleason grade within resolution of millimeters. Similarly, DCE-MRI might show information about the Gleason grade of cancer evident in the enhancement pattern.83

The aforementioned studies have shown that the MR examination carried out before biopsy has the potential to identify and target biopsies for improved detection of prostate cancer. By providing more accurate correlation with Gleason scores, these studies might additionally provide information on ideal treatment strategies. Recently, we evaluated the potential of prebiopsy MRSI to segregate patients who, on prostate biopsy, are more likely to show a malignancy in the PZ of the prostate gland.84 The study included 123 men with elevated PSA or an abnormal DRE. The results of the study suggested that patients who are deemed as malignancy-positive in the PZ by MRSI might be subjected to prostate biopsy to confirm the diagnosis of cancer.

Vilanova et al. reported that a model incorporating MR imaging, MR spectroscopy and free-to-total PSA ratio was significantly more accurate in predicting prostate cancer than models using MR imaging alone, MRS alone or MR imaging and free-to-total PSA ratio combined.85 The usefulness of prebiopsy MRI using T2WI, MRS, DWI and DCE-MRI has also been reported in predicting prostate cancer.86 The model combining all variables was more accurate (95.2%) compared with each variable alone.86 Villeirs et al. carried out a study of 356 patients to assess the ability of combined MRI and MRSI to predict the presence or absence of high-grade prostate cancer in men with elevated PSA.87 The study reported that combined MRI/MRSI had a significantly higher sensitivity for high-grade tumors (92.7%) than for lower-grade tumors (67.6%), and was false positive in just 7.4% cases.

One of the promising roles of MRSI lies in its potential ability to predict the absence of prostate cancer in men with raised serum PSA due to non-malignant causes. This could immediately result in a reduction in the number of patients undergoing prostate biopsies. MRSI has been shown to have a high negative predictive value.49,87,88 A prebiopsy MRSI might be chosen over the invasive biopsy to predict the absence of prostate cancer.88 This will reduce the number of unnecessary biopsies carried out. We tested the hypothesis that MRSI might be able to identify patients with non-cancerous PSA elevation and help avoid unnecessary biopsies.88 We carried out MRSI before biopsy in patients with PSA between 4–10 ng/mL, and followed 36 men out of 155 whose MRSI showed no malignant voxels for at least 18 months (Fig. 5). None of these 36 men had cancer on their initial TRUS-guided biopsies. Interestingly, four patients required repeat biopsy, and one with persistently elevated PSA was diagnosed with prostate cancer after 29 months of initial MRSI. We concluded that prostate biopsy can be deferred in patients with an increased serum PSA between 4 to 10 ng/mL if their MRSI does not show abnormal voxels.


Figure 5. A representative example of T2-weighted axial image of the prostate with an overlaid spectroscopic grid from a patient with negative MRSI findings. The PSA of the patient was 6.05 ng/mL with a history of lower urinary tract symptoms with urgency and nocturia for approximately 1 year, but with no history of trauma.

Download figure to PowerPoint

A few limitations of studies reporting the use of prebiopsy MR examination should be considered. Studies evaluating the prebiopsy population have used TRUS biopsy results as a gold standard, for at least a subgroup of the patients studied. Because TRUS biopsy suffers from sampling errors, it cannot be regarded as a good reference standard. It might not be possible to obtain radical prostatectomy step-section histopathology data on all of the prebiopsy population, which makes comparison with MR data difficult. Increasing the number of cores of biopsy does not solve the problem, and also increases the complications. Other factors that might affect the use of MR examination before biopsy is the burden of endorectal examination, detection of a higher number of insignificant cancers and the cost associated with subjecting patients to MR before proven prostate cancer diagnosis. In the literature, there are no reports on significant difficulty in using endorectal coil or complications arising after its use. MRI evaluation is an expensive examination. The time and resources might be better utilized for such an evaluation by recommending it only for a select group of patients with perceived benefits. Further studies on the cost-analysis need to be designed to answer such questions. These arguments have to be weighed against the benefit of better detection, early treatment and avoiding unnecessary biopsies. Multisite studies are required to validate the clinical utility of prebiopsy MR investigation of the prostate.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References

Prebiopsy MR-based imaging modalities have shown increased clinical value in predicting the presence of cancer, targeting biopsies, increasing biopsy yields and correlating with disease aggressiveness. Specifically, prebiopsy MRSI and diffusion MRI have been reported to be useful in identifying patients who, on prostate biopsy, are more likely to show a malignancy in the peripheral zone of the prostate gland. In addition, carrying out prebiopsy MRI also circumvents the problem of postbiopsy hemorrhage artifacts seen in MR images and, hence, avoids the need to wait 2–3 months for MR imaging after biopsy. These come with the potential problem of higher detection of insignificant cancers and increased costs.


  1. Top of page
  2. Abstract
  3. Introduction
  4. Role of magnetic resonance methods in prostate imaging
  5. Clinical applications of MR studies before biopsy
  6. Conclusions
  7. Conflict of interest
  8. References
  • 1
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 2004; 350: 223946.
  • 2
    Wilson SS, Crawford ED. Screening for prostate cancer: current recommendations. Urol. Clin. North Am. 2004; 31: 21926.
  • 3
    Prostate specific antigen best practice statement: 2009 update. [Cited 27 Aug 2011.] Available from URL:
  • 4
    Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am. 2000; 38: 11538, viii–ix.
  • 5
    Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am. J. Roentgenol. 2009; 192: 147180.
  • 6
    Bonekamp D, Macura KJ. Dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the prostate. Top. Magn. Reson. Imaging 2008; 19: 27384.
  • 7
    Futterer JJ, Heijmink SW, Scheenen TW et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 44958.
  • 8
    Kayhan A, Fan X, Oto A. Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer. Top. Magn. Reson. Imaging 2009; 20: 10512.
  • 9
    Sugahara T, Korogi Y, Kochi M et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J. Magn. Reson. Imaging 1999; 9: 5360.
  • 10
    Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest. Radiol. 2009; 44: 5726.
  • 11
    Yamashita Y, Kumabe T, Higano S, Watanabe M, Tominaga T. Minimum apparent diffusion coefficient is significantly correlated with cellularity in medulloblastomas. Neurol. Res. 2009; 31: 9406.
  • 12
    Woodhams R, Kakita S, Hata H et al. Diffusion-weighted imaging of mucinous carcinoma of the breast: evaluation of apparent diffusion coefficient and signal intensity in correlation with histologic findings. AJR Am. J. Roentgenol. 2009; 193: 2606.
  • 13
    Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am. J. Neuroradiol. 2010; 31: 606.
  • 14
    Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J. Magn. Reson. Imaging 2002; 16: 196200.
  • 15
    Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J. Magn. Reson. Imaging 2004; 20: 65461.
  • 16
    Manenti G, Carlani M, Mancino S et al. Diffusion tensor magnetic resonance imaging of prostate cancer. Invest. Radiol. 2007; 42: 41219.
  • 17
    Gurses B, Tasdelen N, Yencilek F et al. Diagnostic utility of DTI in prostate cancer. Eur. J. Radiol. 2011; 79: 1726.
  • 18
    Shimofusa R, Fujimoto H, Akamata H et al. Diffusion-weighted imaging of prostate cancer. J. Comput. Assist. Tomogr. 2005; 29: 14953.
  • 19
    Sato C, Naganawa S, Nakamura T et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J. Magn. Reson. Imaging 2005; 21: 25862.
  • 20
    Sinha S, Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn. Reson. Med. 2004; 52: 5307.
  • 21
    Henkelman RM, Stanisz GJ, Graham SJ. Magnetization transfer in MRI: a review. NMR Biomed. 2001; 14: 5764.
  • 22
    Arima K, Hayashi N, Yanagawa M et al. The progress in diagnostic imaging for staging of bladder and prostate cancer: endorectal magnetic resonance imaging and magnetization transfer contrast. Hinyokika Kiyo 1999; 45: 5537.
  • 23
    Kumar V, Jagannathan NR, Kumar R et al. Evaluation of the role of magnetization transfer imaging in prostate: a preliminary study. Magn. Reson. Imaging 2008; 26: 6449.
  • 24
    Costello LC, Franklin RB. The intermediary metabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 2000; 59: 26982.
  • 25
    Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 14353.
  • 26
    Marberger H, Marberger E, Mann T, Lutwak-Mann C. Citric acid in human prostatic secretion and metastasizing cancer of prostate gland. Br. Med. J. 1962; 1: 8356.
  • 27
    Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991; 18: 2546.
  • 28
    Costello LC, Franklin RB, Narayan P. Citrate in the diagnosis of prostate cancer. Prostate 1999; 38: 23745.
  • 29
    Jung JA, Coakley FV, Vigneron DB et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 7018.
  • 30
    Jagannathan NR, Kumar V, Kumar R, Thulkar S. Role of magnetic resonance methods in the evaluation of prostate cancer: an Indian perspective. MAGMA 2008; 21: 393407.
  • 31
    Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 1996; 198: 795805.
  • 32
    Kurhanewicz J, Vigneron DB, Hricak H et al. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology 1996; 200: 48996.
  • 33
    Lagemaat MW, Zechmann CM, Futterer JJ et al. Reproducibility of 3D 1 H MR spectroscopic imaging of the prostate at 1.5T. J. Magn. Reson. Imaging 2012; 35: 166173.
  • 34
    Scheidler J, Hricak H, Vigneron DB et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology 1999; 213: 47380.
  • 35
    Wefer AE, Hricak H, Vigneron DB et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J. Urol. 2000; 164: 4004.
  • 36
    Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In: Walsh PC (ed.). Campbell's Urology, 8th edn. Saunders, Philadelphia, PA, 2002; 3058.
  • 37
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56: 10630.
  • 38
    Lattouf JB, Grubb RL III, Lee SJ et al. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007; 99: 10416.
  • 39
    Kumar V, Jagannathan NR, Kumar R et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/mL. NMR Biomed. 2007; 20: 1120.
  • 40
    Chen M, Dang HD, Wang JY et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 2008; 49: 60210.
  • 41
    Chen YJ, Pu YS, Chueh SC, Shun CT, Chu WC, Tseng WY. Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection. J. Magn. Reson. Imaging 2011; 33: 35663.
  • 42
    Yagci AB, Ozari N, Aybek Z, Duzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn. Interv. Radiol. 2011; 17: 1304.
  • 43
    Ahmed HU, Kirkham A, Arya M et al. Is it time to consider a role for MRI before prostate biopsy? Nature Reviews. Clin. Oncol. 2009; 6: 197206.
  • 44
    Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer. Int. J. Urol. 2008; 15: 3226; discussion 327.
  • 45
    Choi MS, Choi YS, Yoon BI et al. The clinical value of performing an MRI before prostate biopsy. Korean J. Urol. 2011; 52: 5727.
  • 46
    Squillaci E, Manenti G, Mancino S et al. MR spectroscopy of prostate cancer. Initial clinical experience. J. Exp. Clin. Cancer Res. 2005; 24: 52330.
  • 47
    Manenti G, Squillaci E, Carlani M, Mancino S, Di Roma M, Simonetti G. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol. Med. 2006; 111: 2232.
  • 48
    Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J. Urol. 2006; 176: 24327.
  • 49
    Kumar V, Jagannathan NR, Kumar R et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn. Reson. Imaging 2006; 24: 5418.
  • 50
    Perdona S, Di Lorenzo G, Autorino R et al. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urol. Oncol. 2011; in press.
  • 51
    Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J. Magn. Reson. Imaging 2007; 25: 14652.
  • 52
    Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging 2010; 31: 62531.
  • 53
    Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis – correlation with biopsy and histopathology. J. Magn. Reson. Imaging 2006; 24: 10813.
  • 54
    Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011; 108: E1718.
  • 55
    Costouros NG, Coakley FV, Westphalen AC et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am. J. Roentgenol. 2007; 188: 81216.
  • 56
    Kozlowski P, Chang SD, Goldenberg SL. Diffusion-weighted MRI in prostate cancer – comparison between single-shot fast spin echo and echo planar imaging sequences. Magn. Reson. Imaging 2008; 26: 726.
  • 57
    Manenti G, Squillaci E, Di Roma M, Carlani M, Mancino S, Simonetti G. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol. Med. 2006; 111: 112433.
  • 58
    Shimizu T, Nishie A, Ro T et al. Prostate cancer detection: the value of performing an MRI before a biopsy. Acta Radiol. 2009; 50: 10808.
  • 59
    Kumar V, Jagannathan NR, Kumar R et al. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed. 2007; 20: 50511.
  • 60
    Nishida S, Kinoshita H, Mishima T, Kurokawa H, Sakaida N, Matsuda T. Prostate cancer detection by prebiopsy 3.0-Tesla magnetic resonance imaging. Int. J. Urol. 2011; 18: 6538.
  • 61
    Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62: 1407.
  • 62
    Kozlowski P, Chang SD, Meng R et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T – quantitative correlation with biopsy. Magn. Reson. Imaging 2010; 28: 6218.
  • 63
    Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 1998; 52: 80813.
  • 64
    Ouzzane A, Puech P, Lemaitre L et al. Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. Urology 2011; 78: 135662.
  • 65
    Yuen JS, Thng CH, Tan PH et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J. Urol. 2004; 171: 14826.
  • 66
    Amsellem-Ouazana D, Younes P, Conquy S et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur. Urol. 2005; 47: 5826.
  • 67
    Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 90310.
  • 68
    Wetter A, Hubner F, Lehnert T et al. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies. Eur. Radiol. 2005; 15: 64552.
  • 69
    Anastasiadis AG, Lichy MP, Nagele U et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur. Urol. 2006; 50: 738748.
  • 70
    Bhatia C, Phongkitkarun S, Booranapitaksonti D, Kochakarn W, Chaleumsanyakorn P. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. J. Med. Assoc. Thai. 2007; 90: 13919.
  • 71
    Testa C, Schiavina R, Lodi R et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed. 2010; 23: 101726.
  • 72
    Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009; 103: 7303.
  • 73
    Schmuecking M, Boltze C, Geyer H et al. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer? Int. J. Radiat. Biol. 2009; 85: 81424.
  • 74
    Sciarra A, Panebianco V, Ciccariello M et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin. Cancer Res. 2010; 16: 187583.
  • 75
    Susil RC, Camphausen K, Choyke P et al. System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magn. Reson. Med. 2004; 52: 6837.
  • 76
    Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz MM. R imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005; 234: 57681.
  • 77
    Krieger A, Susil RC, Menard C et al. Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans. Biomed. Eng. 2005; 52: 30613.
  • 78
    Mozer PC, Partin AW, Stoianovici D. Robotic image-guided needle interventions of the prostate. Rev. Urol. 2009; 11: 715.
  • 79
    Macura KJ, Stoianovici D. Advancements in magnetic resonance-guided robotic interventions in the prostate. Top. Magn. Reson. Imaging 2008; 19: 297304.
  • 80
    Pondman KM, Futterer JJ, ten Haken B et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur. Urol. 2008; 54: 51727.
  • 81
    Xu H, Lasso A, Vikal S et al. Accuracy validation for MRI-guided robotic prostate biopsy. Proc. SPIE 2010; 7625: 76251718.
  • 82
    Nayyar R, Singh P, Gupta NP et al. Upgrading of Gleason score on radical prostatectomy specimen compared to the pre-operative needle core biopsy: an Indian experience. Indian J. Urol. 2010; 26: 569.
  • 83
    Rouviere O, Raudrant A, Ecochard R et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur. Radiol. 2003; 13: 93142.
  • 84
    Kumar V, Jagannathan NR, Kumar R et al. Potential of (1)H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy. J. Magn. Reson. Imaging 2009; 30: 8428.
  • 85
    Vilanova JC, Comet J, Barcelo-Vidal C et al. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Radiology 2009; 253: 13543.
  • 86
    Vilanova JC, Barcelo-Vidal C, Comet J et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. AJR Am. J. Roentgenol. 2011; 196: W71522.
  • 87
    Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur. J. Radiol. 2011; 77: 3405.
  • 88
    Kumar R, Nayyar R, Kumar V et al. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/mL: a follow-up study. Urology 2008; 72: 85963.